<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910464</url>
  </required_header>
  <id_info>
    <org_study_id>17300607</org_study_id>
    <nct_id>NCT04910464</nct_id>
  </id_info>
  <brief_title>Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis</brief_title>
  <official_title>Could Early Tranexamic Acid Safely Serve as an Anti-inflammatory Treatment for Patients With Sepsis? A Randomized Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, our aim is to investigate the role tranexamic acid in modulating inflammation&#xD;
      in patients with sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients or their relatives.Patients will&#xD;
      be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.&#xD;
&#xD;
      In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline,&#xD;
      intravenous over 10 minutes as soon as possible but no later than three hours after&#xD;
      diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal&#xD;
      saline for the first 3 days. In (Group C) administer the same volume (100 ml normal&#xD;
      saline)and same duration (first three days)for controlled patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>7days</time_frame>
    <description>Short-term ICU mortality within 7days of admission and intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil/lymphocyte ratio (NLR)</measure>
    <time_frame>4 days</time_frame>
    <description>From complete blood count, divide absolute number of neutrophils on lymphocyte to assess and follow up the inflammatory response in sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6) serum level</measure>
    <time_frame>4 days</time_frame>
    <description>Measurement of interleukin-6 (IL-6) serum level to assess and follow up the inflammatory response in sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow coma scale (GCS)</measure>
    <time_frame>5 days</time_frame>
    <description>Assessing the conscious level of patients by Glasgow Coma Scale (3_15)after ICU admission and intervention start give an idea on brain dysfunction in sepsis where high scores are associated with low mortality and low scores are associated with high mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>7 days</time_frame>
    <description>Days of patients admission in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>7 days</time_frame>
    <description>Days of patients admission in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Give the same volume (100 ml normal saline) and same duration (first three days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Cyclokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>administer the same volume (100ml normal saline) and same duration (first three days).</description>
    <arm_group_label>Saline placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will&#xD;
             be diagnosed with sepsis by qSOFA ≥2&#xD;
&#xD;
          -  &amp; needed ICU admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic renal failure&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Bleeding disorders or current anticoagulant therapy&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Impaired color vision&#xD;
&#xD;
          -  Severe vascular ischemia, history of venous thrombosis &amp; pulmonary embolism&#xD;
&#xD;
          -  Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs&#xD;
             not discontinued before ICU admission&#xD;
&#xD;
          -  Allergy to tranexamic acid (TXA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Omar makram</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Soliman</last_name>
    <phone>01101266040</phone>
    <email>omarmakram347@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

